MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
36.17
-0.56
-1.52%
After Hours: 36.59 +0.42 +1.15% 19:30 09/25 EDT
OPEN
37.00
PREV CLOSE
36.73
HIGH
37.00
LOW
36.14
VOLUME
2.68M
TURNOVER
--
52 WEEK HIGH
49.70
52 WEEK LOW
8.77
MARKET CAP
4.86B
P/E (TTM)
-10.5523
1D
5D
1M
3M
1Y
5Y
1D
Will Positive Phase 3 Anxiety Data Change Definium Therapeutics' (DFTX) Narrative
Simply Wall St · 2d ago
Weekly Report: what happened at DFTX last week (0914-0918)?
Weekly Report · 5d ago
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
NASDAQ · 09/19 23:02
Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?
Simply Wall St · 09/19 21:30
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
TipRanks · 09/19 14:40
10 mid-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:10
Psychedelic: Definium’s LSD-based drug meets endpoints in GAD study
TipRanks · 09/17 13:55
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.